Suppr超能文献

女性尿道癌:临床病理特征的当代回顾,重点关注组织解剖学标志和潜在的分期问题。

Female urethral carcinoma: a contemporary review of the clinicopathologic features, with emphasis on the histoanatomic landmarks and potential staging issues.

机构信息

Departments of Pathology and Urology, Keck School of Medicine, University of Southern California, 90033, USA.

Departments of Pathology and Urology, Keck School of Medicine, University of Southern California, 90033, USA.

出版信息

Hum Pathol. 2022 Nov;129:71-80. doi: 10.1016/j.humpath.2022.08.003. Epub 2022 Aug 28.

Abstract

Primary female urethral carcinoma (PUC-F) accounts for less than 1% of all genitourinary malignancies and comprises a histologically diverse group of tumors that are usually associated with poor prognosis. The carcinomas documented at this site include adenocarcinoma (clear cell adenocarcinoma, columnar cell carcinoma, and Skene gland adenocarcinoma), urothelial carcinoma (UCa), and squamous cell carcinoma (SCC). Recent studies have shown adenocarcinomas to be the most common type of primary urethral carcinoma in females. As most of the urethral carcinomas morphologically resemble carcinomas arising from surrounding pelvic organs or metastases, these should be ruled out before making the diagnosis of PUC-F. These tumors are currently staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. However, the AJCC system has limitations, including the staging of tumors involving the anterior wall of the urethra. Staging systems like the recently proposed histology-based female urethral carcinoma staging system (UCS) takes into account the unique histological landmarks of the female urethra to better stratify pT2 and pT3 tumors into prognostic groups, that correlate with clinical outcomes including recurrence rates, disease-specific and overall survival. Further larger multi-institutional cohorts are however required to validate the results of this staging system. There is very limited information regarding the molecular profiling of PUC-F. Thirty-one percent of clear cell adenocarcinomas have been reported to show PIK3CA alterations, whereas 15% of adenocarcinomas show PTEN mutations. Higher tumor mutational burden and PD-L1 staining have been reported in UCa and SCC. Although multimodality treatment is usually recommended in locally advanced and metastatic disease, the role of immunotherapy and targeted therapy is promising in select PUC-F cases.

摘要

原发性女性尿道癌(PUC-F)占所有泌尿生殖系统恶性肿瘤的不到 1%,包括一组组织学上多样化的肿瘤,通常与预后不良相关。该部位的癌包括腺癌(透明细胞腺癌、柱状细胞癌和斯基恩腺腺癌)、尿路上皮癌(UCa)和鳞状细胞癌(SCC)。最近的研究表明,腺癌是女性原发性尿道癌中最常见的类型。由于大多数尿道癌在形态上类似于来自周围盆腔器官或转移的癌,因此在做出 PUC-F 的诊断之前,应排除这些癌。这些肿瘤目前根据第 8 版美国癌症联合委员会(AJCC)分期系统进行分期。然而,AJCC 系统存在局限性,包括累及尿道前壁的肿瘤分期。最近提出的基于组织学的女性尿道癌分期系统(UCS)等分期系统考虑了女性尿道的独特组织学标志,以便更好地将 pT2 和 pT3 肿瘤分层为预后组,这些组与包括复发率在内的临床结果相关,疾病特异性和总生存率。然而,还需要更大的多机构队列来验证该分期系统的结果。关于 PUC-F 的分子谱的信息非常有限。据报道,31%的透明细胞腺癌显示 PIK3CA 改变,而 15%的腺癌显示 PTEN 突变。在 UCa 和 SCC 中报道了更高的肿瘤突变负担和 PD-L1 染色。虽然通常建议在局部晚期和转移性疾病中采用多模式治疗,但免疫治疗和靶向治疗在选择的 PUC-F 病例中具有广阔的应用前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验